

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 18, 2025

NCI-H1299

RRID:CVCL_0060

Type: Cell Line

Proper Citation

(RRID:CVCL_0060)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0060

Proper Citation: (RRID:CVCL_0060)

Sex: Male

Defining Citation: [PMID:1311061](#), [PMID:1563005](#), [PMID:1565469](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:12068308](#), [PMID:17332333](#), [PMID:18083107](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24335698](#), [PMID:25485619](#), [PMID:25714623](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26929325](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:34737324](#), [PMID:35839778](#), [PMID:36264037](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: NCI-H1299

Synonyms: H1299, H-1299, NCIH1299

Cross References: BTO:BTO_0002552, CLO:CLO_0007986, EFO:EFO_0003043, MCCL:MCC:0000352, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5803, BCRJ:0185, BioGRID_ORCS_Cell_line:234, BioSample:SAMN03471642, BioSample:SAMN03471739, BioSample:SAMN10988385, cancercellines:CVCL_0060, CCRID:1101HUM-PUMC000469, CCRID:1102HUM-NIFDC00050, CCRID:3101HUMSCSP589, CCRID:3101HUMTCHu160, CCRID:4201HUM-CCTCC00640, Cell_Model_Passport:SIDM00649, ChEMBL-Cells:ChEMBL3308501, ChEMBL-Targets:ChEMBL612255, CLS:300485, Cosmic:722069, Cosmic:724831, Cosmic:877265, Cosmic:877418, Cosmic:903585, Cosmic:961838, Cosmic:980971, Cosmic:1004693, Cosmic:1032443, Cosmic:1047106, Cosmic:1066159, Cosmic:1146875, Cosmic:1154606, Cosmic:1175867, Cosmic:1218870, Cosmic:1239925, Cosmic:1609524, Cosmic:1870264, Cosmic:1925845, Cosmic:1995520, Cosmic:2042873, Cosmic:2125178, Cosmic:2630419, Cosmic:2664126, Cosmic:2749161, Cosmic:2772159, Cosmic-CLP:724831, DepMap:ACH-000510, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:724831, GEO:GSM108807, GEO:GSM108808, GEO:GSM185871, GEO:GSM206471, GEO:GSM253382, GEO:GSM274743, GEO:GSM274744, GEO:GSM353229, GEO:GSM434266, GEO:GSM784253, GEO:GSM794311, GEO:GSM827467, GEO:GSM844617, GEO:GSM887355, GEO:GSM888433, GEO:GSM1374698, GEO:GSM1374699, GEO:GSM1670165, IARC_TP53:21537, IARC_TP53:21722, IGRhCellIID:H1299GEO, KCLB:25803, KCLB:91299, LiGeA:CCLE_300, LINCS_LDP:LCL-1609, Lonza:796, MetaboLights:MTBLS873, NCI-DTP:NCI-H1299, PharmacDB:NCIH1299_1006_2019, PRIDE:PXD003743, PRIDE:PXD005291, PRIDE:PXD018581, PRIDE:PXD030304, PRIDE:PXD035746, Progenetix:CVCL_0060, PubChem_Cell_line:CVCL_0060, TOKU-E:2592, TOKU-E:3620, Ubigen:YC-D010, Wikidata:Q5628772

ID: CVCL_0060

Record Creation Time: 20250131T201458+0000

Record Last Update: 20250131T203136+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1299.

No alerts have been found for NCI-H1299.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6282 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://FDILab-SciCrunch.org).

Ramponi V, et al. (2025) H4K20me3-Mediated Repression of Inflammatory Genes Is a Characteristic and Targetable Vulnerability of Persister Cancer Cells. *Cancer research*, 85(1), 32.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Wang L, et al. (2025) Demethylzeylasteral inhibits oxidative phosphorylation complex biogenesis by targeting LRPPRC in lung cancer. *Journal of Cancer*, 16(1), 227.

Wan M, et al. (2025) Lovastatin-mediated pharmacological inhibition of Formin protein DIAPH1 suppresses tumor immune escape and boosts immunotherapy response. *International immunopharmacology*, 144, 113637.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Bagnyukova T, et al. (2024) Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. *Cancer research communications*, 4(5), 1227.

Sun H, et al. (2024) TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT. *iScience*, 27(6), 109869.

Zhang H, et al. (2024) Diverse temporal and spatial mechanisms work, partially through Stanniocalcin-1, V-ATPase and senescence, to activate the extracellular ATP-mediated drug resistance in human cancer cells. *Frontiers in oncology*, 14, 1276092.

Zhu M, et al. (2024) Targeting TOP2B as a vulnerability in aging and aging-related diseases. *Biochimica et biophysica acta. Molecular basis of disease*, 1870(3), 167044.

Yu S, et al. (2024) A non-viral DNA delivery system consisting of multifunctional chimeric peptide fused with zinc-finger protein. *iScience*, 27(4), 109464.

Ge W, et al. (2024) IL-17 induces NSCLC cell migration and invasion by elevating MMP19 gene transcription and expression through the interaction of p300-dependent STAT3-K631 acetylation and its Y705-phosphorylation. *Oncology research*, 32(4), 625.

Hung CH, et al. (2024) Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer. *Nature communications*, 15(1), 7885.

Greenwood HE, et al. (2024) Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. *Nature communications*, 15(1), 10484.

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and

identification of a dual-targeting inhibitor. *EMBO molecular medicine*, 16(4), 885.

Knippler CM, et al. (2024) Bisbiguanide analogs induce mitochondrial stress to inhibit lung cancer cell invasion. *iScience*, 27(4), 109591.

Mondal P, et al. (2024) Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells. *FEBS letters*, 598(12), 1532.

Grze? M, et al. (2024) A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. *Cell death & disease*, 15(8), 638.

M Saini V, et al. (2024) A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer. *Molecular oncology*.

Yang X, et al. (2024) PHLDA2-mediated phosphatidic acid peroxidation triggers a distinct ferroptotic response during tumor suppression. *Cell metabolism*, 36(4), 762.

Myint KZ, et al. (2024) Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. *Pharmaceuticals (Basel, Switzerland)*, 17(2).